CSIMarket
 
Anavex Life Sciences Corp   (AVXL)
Other Ticker:  
 
 
Price: $5.1100 $-0.03 -0.584%
Day's High: $5.28 Week Perf: -1.54 %
Day's Low: $ 5.08 30 Day Perf: -12.5 %
Volume (M): 6,457 52 Wk High: $ 10.45
Volume (M$): $ 32,994 52 Wk Avg: $7.41
Open: $5.09 52 Wk Low: $4.80



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) -
 Employees -
 Revenues (TTM) (Millions $) 3
 Net Income (TTM) (Millions $) -43
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Anavex Life Sciences Corp
Anavex Life Sciences Corp (Anavex) is a biopharmaceutical company that focuses on the development of innovative therapies for the treatment of central nervous system (CNS) diseases. They are dedicated to addressing unmet medical needs and improving the lives of patients suffering from disorders such as Alzheimer's and Parkinson's disease.

Anavex utilizes a proprietary platform called Sigma-1 Receptor (S1R) to develop small molecule drugs that have the potential to modulate multiple CNS pathways. Their lead investigational product, ANAVEX'2-73, targets neurodegenerative and neurodevelopmental diseases. This drug has shown promising results in preclinical and clinical studies, exhibiting both disease-modifying and symptomatic benefits.

The company also has other drug candidates in its pipeline, including ANAVEX'3-71, which is being developed for the treatment of Rett syndrome and other indications. ANAVEX'3-71 has shown positive results in preclinical studies, demonstrating cognitive improvements and beneficial effects on certain molecular markers.

In addition to their drug development efforts, Anavex actively collaborates with leading academic institutions and research organizations to advance their understanding of CNS diseases and identify potential therapeutic targets. They aim to leverage cutting-edge science and technology to develop novel treatments that can significantly impact patients' lives.

Overall, Anavex Life Sciences Corp is a biopharmaceutical company focused on developing innovative therapies for CNS diseases, with a strong commitment to improving patient outcomes and addressing critical unmet medical needs.


   Company Address: 630 5th Avenue New York 10111 NY
   Company Phone Number: 689-3939   Stock Exchange / Ticker: NASDAQ AVXL
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Announcement

Class-Action Lawsuit Targets Anavex Life Sciences Corporation's Alleged Misrepresentation and Deceptive Practices

Published Thu, Mar 14 2024 4:04 PM UTC

Gainey McKenna & Egleston, a New York-based law firm, has recently revealed that a class-action lawsuit has been filed against biopharmaceutical company Anavex Life Sciences Corporation (Anavex) in the United States District Court for the Southern District of New York. This lawsuit represents all individuals and entities who purchased or obtained securities of Anavex between...

Anavex Life Sciences Corp

Anavex Life Sciences Corp's Q4 2023 Revenue Plummets to $0.592 Million: What's Next for this Biopharmaceutical Giant?

Financial News Report: Anavex Life Sciences Corp Reports Zero Gain in Q4 2023; Revenue Drops
Anavex Life Sciences Corp, a clinical-stage biopharmaceutical company, announced its financial results for the October to December 31, 2023, period. The company reported a zero gain of $0.00 per share, compared to a loss of $0.17 per share in the same period last year and a gain of $0.48 per share in the previous reporting period.
The revenue for the quarter declined by 21.96% to $0.59 million from $0.76 million in the comparable period a year ago. Sequentially, revenue deteriorated by 11.627% from $0.67 million. This decline in revenue is in stark contrast to the overall performance of the Biotechnology & Pharmaceuticals industry, which recorded a top-line rise during the same period.

Clinical Study

Anavex Life Sciences Unlocks New Possibilities in Neurodegenerative Disorder Treatment: Groundbreaking Breakthroughs in Clinical Studies

Published Wed, Jan 24 2024 12:30 PM UTC

A Groundbreaking Progress in Neurodegenerative Disorder Treatment: Anavex Life Sciences' Recent Discoveries in Clinical StudiesIn recent years, there has been growing interest in the field of neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and Rett syndrome. These conditions pose significant challenges to patients, their families, and the healt...

Clinical Study

ANAVEX3-71: Promising Potential for Schizophrenia Treatment Enters U.S. Phase 2 Clinical Trial

Published Tue, Jan 16 2024 12:31 PM UTC

In an exciting development for the field of psychiatry, Anavex Life Sciences has recently announced the initiation of a phase 2 clinical trial for its novel investigational drug ANAVEX3-71 in the treatment of schizophrenia. This placebo-controlled trial has successfully obtained clearance from the U.S. Food and Drug Administration (FDA) and is scheduled to commence in the se...

Clinical Study

The Awakening Progress on Rett Syndrome: An Unpacking of Anavex Life Sciences' Breakthrough

Published Tue, Jan 2 2024 1:01 PM UTC

Anavex Life Sciences Corp. is etching its name in the annals of scientific advancements as it recently unpacked exciting updates on its Rett Syndrome Program and the topline results from its EXCELLENCE Clinical Study in Pediatric Rett Syndrome. This update, no doubt, is a major milestone not only for Anavex but also for countless medical practitioners and families grappling ...






 

Anavex Life Sciences's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com